Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following terms were ignored: %, %
The following terms were not found in PubMed: 5BCorporate
Page 1
Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial.
Fizazi K, Morris MJ, Shore ND, Chi KN, Crosby M, de Bono JS, Herrmann K, Roubaud G, Nagarajah J, Fleming M, Lewis B, Nordquist L, Carnahan N, Ghebremariam S, Hertelendi M, Castellano D, Sartor O. Fizazi K, et al. Lancet Oncol. 2025 Jul;26(7):948-959. doi: 10.1016/S1470-2045(25)00189-5. Epub 2025 May 26. Lancet Oncol. 2025. PMID: 40441170 Clinical Trial.
Median follow-up time from randomisation to the third interim analysis data cutoff date (Feb 27, 2024) was 24.11 months (IQR 20.24-27.60) in the [(177)Lu]Lu-PSMA-617 group and 24.13 months (20.24-27.37) in the ARPI change group. [(177)Lu]Lu-PSMA-617 delayed time to …
Median follow-up time from randomisation to the third interim analysis data cutoff date (Feb 27, 2024) was 24.11 months (IQR 20.24-27.60) in …
Content Validity of Two Generic Preference-Based Measures in Retinitis Pigmentosa, Including X-Linked Retinitis Pigmentosa.
Matza LS, Howell TA, Zhang Q, Denee T. Matza LS, et al. Pharmacoecon Open. 2026 Mar;10(2):341-354. doi: 10.1007/s41669-025-00617-8. Epub 2026 Jan 23. Pharmacoecon Open. 2026. PMID: 41575715 Free PMC article.
INTRODUCTION: Retinitis pigmentosa (RP) is a group of retinal diseases characterized by night blindness and impairment in visual field and acuity. ...The relevance of common generic preference-based measures (GPBMs) in visual conditions like XLRP is often questioned. The p …
INTRODUCTION: Retinitis pigmentosa (RP) is a group of retinal diseases characterized by night blindness and impairment in visual fiel …